Archive | July, 2010

“AACC Effect” Rally Rolls On: Abaxis(ABAX),GenProbe (GPRO),and Quidel (QDEL)

The intersection of good earnings and a strong AACC showing boosted Diagnostic stocks this week with the following big movers today on earnings reports: Abaxis (ABAX) $20.81 up $13.7%,GenProbe (GPRO) $45.85 up 8.14%,Neogen (NEOG) $29.85 up 3.4% and Quidel (QDEL) $12.34 up 3.5%.Bruker was also strong up 3% to $13.23. “Mid-Cap” Diagnostic Companies Q2 2010 […]

Continue Reading 0

AACC Notes-Diagnostic Stocks and Rayno Model Portfolio

Here are some brief notes from our visit to the AACC in Anaheim and recent earnings reports. Rayno Diagnostic and Tools Portfolio Abaxis (ABAX)-under review– and Quidel (QDEL) report today.We added Quidel to our model portfolio on 6/16 at $12.40.The stock is trading at around $12 maybe anticipating dilution due to the $130M acquisition of […]

Continue Reading 0

AACC Meeting: Buzz Coming to Fuel the Rally In Diagnostic Stocks

The July 25-29 AACC (American Association of Clinical Chemistry) Meeting in Anaheim will have close to 20,000 clinical lab professionals and over 500 exhibitors . A stock rally in the sector was ignited last week by earnings announcements from four major mid-cap players and new product and technology news should help support the rally.As of […]

Continue Reading 0

Big Movers In Diagnostics Today: Immucor (BLUD) Up 6.5% and Cepheid (CPHD) up 12%

Good financials have perked up interest is mid-cap Diagnostics companies that released results today. Immucor (BLUD) a global leader in automated analysis of blood transfusion systems had revenue of $82.9M up 5% from prior year quarter with diluted earnings of $0.30 per share compared to $0.27 in the prior year quarter.Cash Flow from operations was […]

Continue Reading 0

Gilead Holding Up at $33 on Exhaustion of Negativity

Gilead (GILD) has finally caught some bids today up 0.5% on a volume of 23M (Ave. volume 12M) shares! Among the supporters of the stock are Leerink Swann who maintain their “Market Outperform” and price target of low 40’s and JPMorgan who reiterate their “Overweight”and reduced target of  $5 from $55. JPMorgan says the Street […]

Continue Reading 0

Earnings Reports:Gilead (GILD) and Meridian (VIVO) Get Mixed Reviews

Gilead (GILD) Down on Missed Estimates-Is the  Worst Finally Over for the Stock? Despite its stock being down over 30% from Q1 highs and earnings downgrades in April as a fallout from healthcare reform, the Company still disappoints Wall Street with Net Income of $712.1M or 79 cents a share up from $571M or 61 […]

Continue Reading 0

Funding of Technology Start-Ups and Campus Incubators

The story below published in the June 25 NYT merits further development. We are compiling data on other successful University start-ups and incubators such as the M.I.T deals in the article. The boom in campus incubators with a focus on commercializing inventions and nurturing start-up companies really got accelerated in early 2000 following the 90’s […]

Continue Reading 0

News Update: Hospital Costs Can Go Up as a Result of Bad Trades

The trading mentality and derivatives debacle that  infected our financial system has impacted the financial health of hospitals. Who knew hospital management could do interest- rate swaps? They got crushed and now they are suing Wall Street firms. See WSJ story below. Hospitals Sue Wall Street Over Trades – WSJ.com

Continue Reading 0

Biomarker Diagnostics Drive Personalized Medicine #1 Update

But Path to Market is Still Rife with Hurdles Convergence of Genomics and Medicine At the 2010 BIO Conference in Chicago with about 15,000 attendees there were ten Breakout Sessions on Biomarkers (BM) encompassing Intellectual Property, commercialization, reimbursement, drug development and diagnostics. This explosive new technology niche is a nascent paradigm for exploiting breakthroughs in […]

Continue Reading 0